Inhalační anticholinergika a fixní trojkombinace Enerzair® v léčbě průduškového astmatu – od teorie k praxi.

Title in English Inhalation anticholinergics and fixed triple combination Enerzair® in the treatment of bronchial asthma – from theory to practice.


Year of publication 2021
Type Article in Periodical
Magazine / Source časopis Remedia
MU Faculty or unit

Faculty of Medicine

Keywords bronchial asthma;inhalation anticholinergics;LAMA;triple combination of ICS/LABA/LAMA;Enerzair;Breezhaler
Attached files
Description A considerable number of patients with bronchial asthma are not under satisfactory control even with treatment intensification combining inhalation corticosteroid (ICS) with another treatment modality such as long-acting ß2 agonist (LABA). The addition of long-acting muscarinic antagonists (LAMA) to triple combination has the potential to ensure sufficient control in these cases, with the maintenance of complete treatment tolerance. Currently, there are three inhalation drugs containing LAMA indicated and reimbursed in the Czech Republic, except for asthma-COPD overlap syndrome. One of them is a fixed triple combination of ICS/LABA/LAMA in the Breezhaler® inhaler called Enerzair®. The article follows the pharmacological profiles of Enerzair® Breezhaler® published earlier in this magazine, and reflects the use of inhalation anticholinergics, specifically with Enerzair®, in the practice of asthmatologists.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info